Arcus Biosciences Inc
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
RCUS$18.67-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Years ended December 31, 2023, 2022 and 2021
| Number of shares of common stock | Common stock and additionalpaid-in capital | Accumulated deficit | Accumulatedothercomprehensive loss | Totalstockholders’ equity | |
|---|---|---|---|---|---|
| Balance at December 31, 2020 | 63.7 | $830 | $(328) | $— | $502 |
| Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 14, Stockholders' Equity) | 5.7 | 220 | — | — | 220 |
| Issuance of common stock in connection with our equity award programs | 1.4 | 13 | — | — | 13 |
| Stock-based compensation | — | 55 | — | — | 55 |
| Other comprehensive loss | — | — | — | (1) | (1) |
| Net income | — | — | 53 | — | 53 |
| Balance at December 31, 2021 | 70.8 | 1,118 | (275) | (1) | 842 |
| Issuance of common stock in connection with our equity award programs | 2.1 | 23 | — | — | 23 |
| Stock-based compensation | — | 65 | — | — | 65 |
| Other comprehensive loss | — | — | — | (6) | (6) |
| Net loss | — | — | (267) | — | (267) |
| Balance at December 31, 2022 | 72.9 | 1,206 | (542) | (7) | 657 |
| Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 14, Stockholders' Equity) | 1.2 | 25 | — | — | 25 |
| Issuance of common stock in connection with our equity award programs | 1.4 | 7 | — | — | 7 |
| Stock-based compensation | — | 73 | — | — | 73 |
| Other comprehensive gain | — | — | — | 7 | 7 |
| Net loss | — | — | (307) | — | (307) |
| Balance at December 31, 2023 | 75.5 | $1,311 | $(849) | $— | $462 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.